Suffering a series of setbacks, Eli Lilly's oncology group quietly executes 2 of its top mid-stage drugs
Eli Lilly took a hit Tuesday morning as the pharma giant revealed just how painful its withdrawal of Lartruvo will be for its oncology operations while the Cialis franchise gets eaten up by generics. Less visible was a decision to dump two mid-stage drugs from its pipeline operations, both of which had figured prominently as one of its best longterm hopes in the field.
Out in the Q1 cleanup at Lilly is the CHK1 drug prexasertib (LY2606368) and their Phase II PI3k/mTOR inhibitor, LY3023414. Both of these drugs were spotlighted in the summer of 2017, as Eli Lilly announced plans to concentrate their R&D group in oncology on 7 key programs they felt had the best shot at going on to becoming major players in the market.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 62,300+ biopharma pros reading Endpoints daily — and it's free.